Table 4.

Local and systemic side effects of Slovak healthcare workers who received BNT162b2 and stratified by gender, February–March 2021 (n = 522).

Variable	Outcome	Female (n = 402)	Male (n = 120)	Total (n = 522)	Sig.
Local Side Effects	Injection Site Pain	351 (87.3%)	94 (78.3%)	445 (85.2%)	0.015
	Injection Site Swelling	42 (10.4%)	11 (9.2%)	53 (10.2%)	0.683
	Injection Site Redness	36 (9%)	8 (6.7%)	44 (8.4%)	0.428
	Intensity (0–3)	1.07 ± 0.62	0.94 ± 0.69	1.04 ± 0.64	0.016
	Total (n)	354 (88.1%)	94 (78.3%)	448 (85.8%)	0.007
Systemic Side Effects	Fatigue	236 (58.7%)	47 (39.2%)	283 (54.2%)	<0.001
	Headache	150 (37.3%)	29 (24.2%)	179 (34.3%)	0.008
	Fever	64 (15.9%)	16 (13.3%)	80 (15.3%)	0.490
	Chills	112 (27.9%)	26 (21.7%)	138 (26.4%)	0.177
	Muscle Pain	119 (29.6%)	29 (24.2%)	148 (28.4%)	0.246
	Joint Pain	79 (19.7%)	13 (10.8%)	92 (17.6%)	0.026
	Nausea	40 (10%)	9 (7.5%)	49 (9.4%)	0.419
	Malaise	86 (21.4%)	21 (17.5%)	107 (20.5%)	0.354
	Lymphadenopathy	34 (8.5%)	5 (4.2%)	39 (7.5%)	0.117
	Intensity (0–9)	2.29 ± 2.09	1.62 ± 2.00	2.14 ± 2.08	<0.001
	Total	304 (75.6%)	64 (53.3%)	368 (70.5%)	<0.001
Side Effects Duration	One Day	206 (54.9%)	63 (61.8%)	269 (56.4%)	0.809
	Three Days	128 (34.1%)	34 (33.3%)	162 (34%)	0.466
	Five Days	17 (4.5%)	4 (3.9%)	21 (4.4%)	0.796
	One Week	9 (2.4%)	1 (1%)	10 (2.1%)	0.467
	>One Week	13 (3.5%)	0 (0%)	13 (2.7%)	0.046
	>One Month	2 (0.5%)	0 (0%)	2 (0.4%)	1.000
General Side Effects	Intensity (0–12)	3.34 ± 2.33	2.57 ± 2.24	3.16 ± 2.33	<0.001
	Total	375 (93.3%)	103 (85.8%)	478 (91.6%)	0.010
Severe Side Effects	Total	2 (0.5%)	0 (0%)	2 (0.4%)	1.000

Chi-squared test (χ²), Fisher’s exact test, and Mann–Whitney test (U) were used with a significance level (Sig.) of < 0.05.